Article Text

Download PDFPDF
Transfer for primary angioplasty: who and how?
  1. M Dalby,
  2. G Montalescot
  1. Institut de Cardiologie, Pitie-Salpetriere University Hospital, 47 Boulevard de l’Hopital, 75013 Paris, France
  1. Correspondence to:
    Dr G Montalescot, Institut de Cardiologie, Bureau 2–236, Pitie-Salpetriere University Hospital, 47 Boulevard de l’Hopital, 75013 Paris, France;
    gilles.montalescot{at}psl.ap-hop-paris.fr

Abstract

Randomised trials have led to the conclusion that percutaneous coronary intervention (PCI) is the best reperfusion strategy for most patients with acute myocardial infarction (AMI). However, these trials have limited application to routine practice. Modern trials of mechanical reperfusion strategies need to take account of logistics, transfer times, and adjunctive drug treatment during transfer (facilitated PCI). Such PCI protocols need to be judged against very early thrombolysis with modern agents. This has been the thrust behind a series of recent studies addressing these “real world” issues in early AMI management

  • transfer
  • primary angioplasty
  • stenting
  • glycoprotein IIb/IIIa antagonist
  • AMI, acute myocardial infarction
  • PCI, percutaneous coronary intervention
  • tPA, tissue-type plasminogen activator

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Miscellanea
    BMJ Publishing Group Ltd and British Cardiovascular Society